Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
2021/10/29 by Eleanor J. Cole, Eleanor Cole, Angela Phillips +34 · 1 voice · 40 citations
Medicine · Neuroscience · #Neurological disorders and treatments #Transcranial Magnetic Stimulation Studies #Vagus Nerve Stimulation Research
paper · doi:10.1176/appi.ajp.2021.20101429
Abstract
OBJECTIVE: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression. METHODS: Participants with treatment-resistant depression currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. The primary outcome was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment. RESULTS: At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT. The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group. CONCLUSIONS: SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression. Further trials are needed to determine SNT's durability and to compare it with other treatments.
Citations
Cited by
- Personalized and Circuit-Based Transcranial Magnetic Stimulation: Evidence, Controversies, and Opportunities
- Contrasting effects of global and local cortical activity on the regulation of sleep
- Network-based near-scalp personalized brain stimulation targets
- Target-Specificity and Repeatability in Neuro-Cardiac-Guided TMS for Heart-Brain Coupling
- Reward circuitry predicts the effects of fMRI-guided accelerated prolonged iTBS in treatment-resistant depression
- A precision functional atlas of personalized network topography and probabilities
- RNA high-throughput sequencing and clinical outcome validation indicate that long non-coding RNAs are biomarkers in the peripheral blood of patients with major depressive disorder
- Trigeminal nerve stimulation as an active control condition in TMS clinical trials: Evidence from heart-brain coupling and clinical outcomes
- Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology
- Assessing the efficacy and reproducibility of four common repetitive transcranial magnetic stimulation protocols: A sham-controled study
- Opportunities and obstacles in non-invasive brain stimulation
- Anxious individuals shift emotion control from lateral frontal pole to dorsolateral prefrontal cortex
- Clinical effectiveness of switching to right lateral orbitofrontal cortex-TMS after failure of sequential bilateral dorsolateral prefrontal-TMS in major depression
- Why health authorities should endorse rTMS for treatment-resistant depression
- Subgenual anterior cingulate cortex functional connectivity abnormalities in depression: insights from brain imaging big data and precision-guided personalized intervention via transcranial magnetic stimulation
- Concurrent TMS-fMRI: Technical Challenges, Developments, and Overview of Previous Studies. [europepmc]
- Sex/Gender as a Factor That Influences Transcranial Magnetic Stimulation Treatment Outcome: Three Potential Biological Explanations. [europepmc]
- The Problem and Potential of TMS' Infinite Parameter Space: A Targeted Review and Road Map Forward. [europepmc]
- Evidence of Neuroplastic Changes after Transcranial Magnetic, Electric, and Deep Brain Stimulation. [europepmc]
- Automated optimization of TMS coil placement for personalized functional network engagement. [europepmc]
- Accelerated Repetitive Transcranial Magnetic Stimulation to Treat Major Depression: The Past, Present, and Future. [europepmc]
- Accelerated TMS - moving quickly into the future of depression treatment. [europepmc]
- Precision Neuroimaging for Localization-Related Psychiatry. [europepmc]
- Brain connectivity in major depressive disorder: a precision component of treatment modalities? [europepmc]
- How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both? [europepmc]
- Regulatory Clearance and Approval of Therapeutic Protocols of Transcranial Magnetic Stimulation for Psychiatric Disorders. [europepmc]
- The future of brain circuit-targeted therapeutics. [europepmc]
- Optimizing TMS Coil Placement Approaches for Targeting the Dorsolateral Prefrontal Cortex in Depressed Adolescents: An Electric Field Modeling Study. [europepmc]
- A randomized trial comparing beam F3 and 5.5 cm targeting in rTMS treatment of depression demonstrates similar effectiveness. [europepmc]
- Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment. [europepmc]
- Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode: A Randomized Clinical Trial. [europepmc]
- Optimization Strategies of Transcranial Magnetic Stimulation in Major Depressive Disorder. [europepmc]
- Accelerated Theta Burst Stimulation: Safety, Efficacy, and Future Advancements. [europepmc]
- Chronometric TMS-fMRI of personalized left dorsolateral prefrontal target reveals state-dependency of subgenual anterior cingulate cortex effects. [europepmc]
- Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder. [europepmc]
- TMS provokes target-dependent intracranial rhythms across human cortical and subcortical sites. [europepmc]
- Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis. [europepmc]
- Psilocybin desynchronizes the human brain. [europepmc]
- Structural neural plasticity evoked by rapid-acting antidepressant interventions. [europepmc]
- Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. [europepmc]
Discussions
Related